Genmab A/S (OTCMKTS:GNMSF) Short Interest Down 23.5% in February

Genmab A/S (OTCMKTS:GNMSF) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a drop of 23.5% from the February 13th total of 79,900 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 300 shares, the days-to-cover ratio is currently 203.7 days.

Genmab A/S Stock Performance

OTCMKTS:GNMSF traded down $0.90 during trading hours on Wednesday, reaching $204.08. The stock had a trading volume of 223 shares, compared to its average volume of 3,048. The stock has a 50 day simple moving average of $210.60 and a 200 day simple moving average of $221.88. Genmab A/S has a 12-month low of $186.61 and a 12-month high of $310.56. The stock has a market cap of $13.48 billion, a P/E ratio of 11.65 and a beta of 1.08.

Genmab A/S (OTCMKTS:GNMSF) last released its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.